HOME >> MEDICINE >> NEWS
Investigational drug brings new hope to kidney cancer patients

Preliminary results from a phase II trial of an investigational drug known as BAY 43-9006 demonstrate a significant short-term benefit for patients with advanced renal cell cancer, researchers from the University of Chicago and four other centers reported at the American Association of Cancer Research meeting in Boston, November 20.

Only 10 to 15 percent of patients with metastatic kidney cancer respond to standard immunotherapy, and there are no standard effective therapies for patients who fail or can't tolerate standard immunotherapy. In this study, however, 42 percent (21 of 50) of patients had their tumors shrink at least 25 percent within the first 12 weeks. Six of those patients had a reduction of 50 percent or more.

Another 26 percent (13 patients) had their tumors stabilize within 25 percent of pre-treatment size. The remaining 32 percent left the study because of progressive disease or adverse effects, such as a painful rash or diarrhea.

"This is the most exciting thing in oncology since Gleevec," said the study's lead investigator, Mark Ratain, M.D., professor of medicine and chief of clinical pharmacology at the University of Chicago. "All but one of the kidney cancer patients in this study had advanced disease that did not respond to at least one previous systemic treatment, yet almost half of them had a rapid and very encouraging response to this drug."

The study also served to validate a new approach to phase II trial design. Most phase II trials test the effects of a new drug on patients with a specific disease, such as colon cancer, and limit the goal to determining the percentage of patients who have at least a 50% reduction in tumor size. This study, a "randomized discontinuation trial," enrolled patients with many different tumor types for 12 weeks, then randomized patients with stable disease to placebo vs. continued treatment.

"This approach allows us to test a new drug for effects in many tumor
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
20-Nov-2003


Page: 1 2 3 4 5

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. Anniversary of one of the largest hepatitis A outbreaks in the US brings experts together
8. Futuristic system brings vision to blind
9. New fund brings children from Europe for lifesaving surgery
10. Childrens Cancer Fund brings world-class pediatric cancer specialist to Dallas
11. Womens and Childrens Hospital, Adelaide brings home national Diamond Serif Award

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2019)... ... ... Hoban Law Group is proud to be partnering with Hemp Industries Association ... help educate the public about the most sweeping cannabis reform policy that has ever ... Times Square,” said Hoban Law Group Founder & President Bob Hoban. , When ...
(Date:5/23/2019)... (PRWEB) , ... May 23, 2019 , ... More ... eye's lens, which blocks or changes the passage of light into the eye. ... June as Cataract Awareness Month to educate the public on risk factors, symptoms and ...
(Date:5/23/2019)... ... May 23, 2019 , ... ... announced that Lean Human Capital has selected the winners of its 2019 ... Capital by HealthcareSource has recognized excellence in healthcare recruitment. All winners have been ...
(Date:5/22/2019)... ... May 23, 2019 , ... 5 Design Change Considerations to Stay ... EDT, https://www.fdanews.com/5designchange , Do devicemakers read the fine print when changing a ... the i’s and cross all the t’s may result in inspection failures as well ...
(Date:5/22/2019)... , ... May 22, 2019 , ... With record-breaking starting positions, three drivers from ... Ed Jones have qualified their Chevrolets for the team’s entry in the 103rd ... NTT IndyCar Series qualifying run, Pigot was sitting in pole position in his No. 21 ...
Breaking Medicine News(10 mins):
(Date:5/23/2019)... (PRWEB) , ... May 23, 2019 , ... Educators at ... and Arts Grant from California Casualty at http://www.calcasmusicartsgrant.com . The entry deadline is ... and instructors and hear over and over how their arts and performance programs could ...
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... ... Finance Practice, is pleased to announce the successful closing of the $22,375,000 Series ... the Health and Educational Facilities Board of the Metropolitan Government of Nashville and ...
(Date:5/22/2019)... EDMOND, Okla. (PRWEB) , ... May 22, 2019 ... ... (CBD) industry, has released two new products, Ultra-Relief and Ultra-Relax, that are designed ... relaxation. The products do not contain CBD, but instead contain terpenes and other ...
Breaking Medicine Technology:
Cached News: